Nothing Special   »   [go: up one dir, main page]

MA46990B1 - Compositions glp-1 et ses utilisations - Google Patents

Compositions glp-1 et ses utilisations

Info

Publication number
MA46990B1
MA46990B1 MA46990A MA46990A MA46990B1 MA 46990 B1 MA46990 B1 MA 46990B1 MA 46990 A MA46990 A MA 46990A MA 46990 A MA46990 A MA 46990A MA 46990 B1 MA46990 B1 MA 46990B1
Authority
MA
Morocco
Prior art keywords
compositions
glp
kits
phenol
preparation
Prior art date
Application number
MA46990A
Other languages
English (en)
Other versions
MA46990A (fr
Inventor
Møller Eva Horn
Sørensen Michael Duelund
Joakim Lundqvist
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59713860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46990(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA46990A publication Critical patent/MA46990A/fr
Publication of MA46990B1 publication Critical patent/MA46990B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques du sémaglutide peptidique glp-1 ne comprenant pas plus de 0,01 % (p/p) de phénol, la préparation de celles-ci, des trousses comprenant de telles compositions ainsi que des utilisations de celles-ci.
MA46990A 2017-08-24 2018-08-24 Compositions glp-1 et ses utilisations MA46990B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17187676 2017-08-24
PCT/EP2018/072835 WO2019038412A1 (fr) 2017-08-24 2018-08-24 Compositions de glp-1 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA46990A MA46990A (fr) 2019-05-01
MA46990B1 true MA46990B1 (fr) 2024-03-29

Family

ID=59713860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46990A MA46990B1 (fr) 2017-08-24 2018-08-24 Compositions glp-1 et ses utilisations

Country Status (24)

Country Link
US (4) US10888605B2 (fr)
EP (2) EP4360651A3 (fr)
JP (1) JP6633777B2 (fr)
KR (1) KR102665710B1 (fr)
CN (1) CN111050750B (fr)
AR (1) AR112480A1 (fr)
AU (2) AU2018321157B2 (fr)
BR (1) BR112020002804A2 (fr)
CA (1) CA3082033A1 (fr)
CL (2) CL2020000422A1 (fr)
CO (1) CO2020002647A2 (fr)
ES (1) ES2976496T3 (fr)
HR (1) HRP20240485T1 (fr)
HU (1) HUE066356T2 (fr)
IL (1) IL272232B1 (fr)
MA (1) MA46990B1 (fr)
MX (1) MX2020001525A (fr)
PE (1) PE20211202A1 (fr)
PH (1) PH12020550051A1 (fr)
PL (1) PL3474820T3 (fr)
RS (1) RS65380B1 (fr)
SG (1) SG11202000940XA (fr)
TW (3) TWI783890B (fr)
WO (1) WO2019038412A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
AU2019216442A1 (en) 2018-02-02 2020-08-20 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EP3897570A1 (fr) * 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant un analogue de glp -1
WO2020190757A1 (fr) * 2019-03-15 2020-09-24 Novetide Ltd. Procédés améliorés pour la préparation de semaglutide
BR112021016694A2 (pt) * 2019-03-15 2021-10-13 Novo Nordisk A/S Processo para secagem por pulverização de uma solução de alimentação, produto obtenível pelo processo, e, composição farmacêutica
WO2020201280A1 (fr) * 2019-04-01 2020-10-08 Novo Nordisk A/S Anticorps dirigés contre le liraglutide et leur utilisation
WO2020208541A1 (fr) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprenant un analogue de glp-1
WO2021105393A1 (fr) * 2019-11-29 2021-06-03 Novo Nordisk A/S Procédés d'obtention de compositions de glp-1 stables
WO2021123228A1 (fr) * 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp-1
AU2021207313A1 (en) * 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN114146163B (zh) * 2021-12-07 2023-09-26 苏州天马医药集团天吉生物制药有限公司 司美格鲁肽制剂的制备方法
CN114660214B (zh) * 2022-02-18 2024-04-05 兰州积石药业有限公司 一种司美格鲁肽的液相色谱检测方法及其应用
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
WO2024148155A1 (fr) 2023-01-06 2024-07-11 Nano Precision Medical, Inc. Formulations, dispositifs et méthodes pour un agoniste de glp-1
KR20240149356A (ko) 2023-04-05 2024-10-14 주식회사 아울바이오 Glp-1 수용체 작용제, gip/glp-1 수용체 이중작용제, 및 glp-1/gip/gcg 수용체 삼중작용제로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 액상 제형 및 미립구 제형을 포함하는 약학 조성물

Family Cites Families (451)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444570A (en) 1948-07-06 Drive for counter numeral wheels
GB735443A (en) 1952-09-02 1955-08-24 English Numbering Machines Improvements in or relating to counting devices
US2828742A (en) 1957-05-02 1958-04-01 American Home Prod Cartridge-needle unit
NL121491C (fr) 1963-05-02
US3318289A (en) 1965-05-11 1967-05-09 Northern Ind Products Bi-stable mechanism
CH499734A (de) 1968-07-19 1970-11-30 Kienzle Apparate Gmbh Klinkengesperre als Einrichtungs- und Überholkupplung
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US4282316A (en) 1979-09-11 1981-08-04 Modrovich Ivan Endre Stabilized enzymic solutions for determining urea
MC1379A1 (fr) 1980-03-21 1982-01-19 Wellcome Found Formule pharmaceutique isotonique stabilisee contenant un compose du mercure comme agent de conservation
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
IE52621B1 (en) 1981-02-12 1988-01-06 Turner Robert Charles Dose metering plunger devices for use with syringes
US4568335A (en) 1981-08-28 1986-02-04 Markwell Medical Institute, Inc. Device for the controlled infusion of medications
DE3204178C2 (de) 1982-02-06 1986-03-20 Eppendorf Gerätebau Netheler + Hinz GmbH, 2000 Hamburg Pipettiervorrichtung
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
GB2141799B (en) 1983-06-03 1986-07-16 Diehl Gmbh & Co An adjusting ratchet mechanism for a time switch
DE3468173D1 (en) 1983-09-07 1988-02-04 Disetronic Ag Portable infusion apparatus
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60129941U (ja) 1984-02-09 1985-08-31 テルモ株式会社 医療用器具
US4592745A (en) 1984-02-29 1986-06-03 Novo Industri A/S Dispenser
FR2583291A1 (fr) 1985-06-14 1986-12-19 Hazon Bernard Dispositif d'avancement pas a pas du piston de seringues par double vis coaxiale avec controle du debit d'injection. application aux injections medicamenteuses intra-dermiques repetitives
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
JPH0613052B2 (ja) 1985-11-08 1994-02-23 デイゼトロニツク アクチエンゲゼルシヤフト 注射装置
DE3609555A1 (de) 1986-03-21 1987-09-24 Josef Porner Blutentnahmespritze
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
WO1987006941A1 (fr) 1986-05-05 1987-11-19 The General Hospital Corporation Hormone insulinotrope
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
DE3645245C2 (de) 1986-11-14 1994-01-27 Haselmeier Wilhelm Fa Injektionsgerät
US5716990A (en) 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
DK177187A (da) 1987-04-07 1988-10-08 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glasampul
DE3715258C2 (de) 1987-05-08 1996-10-31 Haselmeier Wilhelm Fa Injektionsgerät
AU616411B2 (en) 1987-05-14 1991-10-31 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
GB8713810D0 (en) 1987-06-12 1987-07-15 Hypoguard Uk Ltd Measured dose dispensing device
FI883338A (fi) 1987-07-16 1989-01-17 Bristol Myers Co Vattenloesningar av doxorubicinhydroklorid.
IT1222331B (it) 1987-08-25 1990-09-05 Bruno Micovilovich Siringa di sicurezza per usi parentali,a disimpegno autonomo e rapido dell'ago dopo l'uso
US4919596A (en) 1987-12-04 1990-04-24 Pacesetter Infusion, Ltd. Fluid delivery control and monitoring apparatus for a medication infusion system
US4833379A (en) 1988-01-13 1989-05-23 Sherwood Medical Company Motor control fail-safe circuit
CH675078A5 (fr) 1988-01-22 1990-08-31 Nosta Ag
DE3900926C2 (de) 1988-02-08 1999-05-12 Disetronic Licensing Ag Spritzenförmiges Injektionsgerät und Injektionsgerätebaukasten
DK166948B1 (da) 1988-02-10 1993-08-09 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glastubule
US4973318A (en) 1988-02-10 1990-11-27 D.C.P. Af 1988 A/S Disposable syringe
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
DE58908873D1 (de) 1988-09-12 1995-02-23 Graesslin Kg Richtgesperre für eine Schaltuhr.
GB8900763D0 (en) 1989-01-13 1989-03-08 Kabi Vitrum Peptide Hormones A Multi-dose syringe
US5216437A (en) 1989-02-02 1993-06-01 Canon Kabushiki Kaisha Ink, and recording method making use of same
DK68789A (da) 1989-02-14 1990-08-15 Novo Nordisk As Injektionspen
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
WO1990011296A1 (fr) 1989-03-20 1990-10-04 The General Hospital Corporation Hormone insulinotrope
JP2822447B2 (ja) 1989-05-19 1998-11-11 住友電気工業株式会社 酸化物超電導線材の製造方法および装置
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
DE3927286C2 (de) 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
EP0431679B1 (fr) 1989-12-05 1994-10-19 Merck & Co. Inc. Procédé de stabilisation de protéines recombinantes de surface du virus de l'hépatitis B à partir de levure
DK17890A (da) 1990-01-22 1991-07-23 Novo Nordisk As Fremgangsmaade og apparat til opblanding og injicering af et laegemiddel
WO1991011457A1 (fr) 1990-01-24 1991-08-08 Buckley Douglas I Analogues de glp-1 utiles dans le traitement du diabete
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
GB9007113D0 (en) 1990-03-29 1990-05-30 Sams Bernard Dispensing device
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5226896A (en) 1990-04-04 1993-07-13 Eli Lilly And Company Dose indicating injection pen
IT220491Z2 (it) 1990-04-13 1993-09-24 Stilolinea Srl Penna a sfera del tipo a punta scrivente rientrante
AU7880991A (en) 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
JP3042710B2 (ja) 1990-09-21 2000-05-22 ノボ ノルディスク アクティーゼルスカブ ペンシリンジアセンブリー
US5284480A (en) 1990-11-09 1994-02-08 Medtronic, Inc. Inflation/deflation syringe with threaded plunger
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
US5331954A (en) 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
AU641206B2 (en) 1991-01-22 1993-09-16 Eli Lilly And Company Multiple dose injection pen
DE69203472T2 (de) 1991-02-07 1996-01-04 Terumo Corp Dosiereinrichtung für Injektor.
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE167229T1 (de) 1991-03-27 1998-06-15 Novo Nordisk As Katalase, ihre herstellung und verwendung
US5258377A (en) 1991-04-08 1993-11-02 Taiho Pharmaceutical Co., Ltd. 2-spirocyclopropyl 4-acylcephems
DE4112259A1 (de) 1991-04-15 1992-10-22 Medico Dev Investment Co Injektionsgeraet
DK68991D0 (da) 1991-04-17 1991-04-17 Novo Nordisk As Manifold
US5645052A (en) 1991-04-26 1997-07-08 The Boc Group Plc Anaesthetic vaporizer with expandable/contractable reservoir for pumping liquid anaesthetic
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
EP0525525B1 (fr) 1991-07-24 1995-05-03 Medico Development Investment Company Injecteur
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK194291D0 (da) 1991-11-29 1991-11-29 Novo Nordisk As Sproejte til automatisk injektion.
US5611783A (en) 1991-11-29 1997-03-18 Novo Nordisk A/S Pen-shaped syringe
US5246417A (en) 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
FR2686460B1 (fr) 1992-01-20 1994-03-11 Labinal Precision Mecanique Organe de contact electrique femelle.
US5279585A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Medication delivery pen having improved dose delivery features
CH682968B5 (fr) 1992-02-12 1994-06-30 Rolex Montres Procédé de fabrication d'un joint et joint pour dispositif de commande étanche pour montre obtenu selon ce procédé.
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
DE4208677A1 (de) 1992-03-18 1993-09-23 Injecta Gmbh Steinach Injektionsvorrichtung, insbesondere fuer sehgeschaedigte diabetiker
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DE69319107T2 (de) 1992-03-25 1999-02-25 Tebro S.A., Luxembourg Pulverabgabevorrichtung für medizinische inhalationstherapien
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5271527A (en) 1992-04-02 1993-12-21 Habley Medical Technology Corporation Reusable pharmaceutical dispenser with full stroke indicator
US5281198A (en) 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
ES2098739T3 (es) 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
WO1993025579A1 (fr) 1992-06-15 1993-12-23 Pfizer Inc. Derives d'insulinotropine et de peptide analogue au glucagon
UA26190C2 (uk) 1992-07-28 1999-07-19 Сейфтек Ай Лімітед Шприц
GB9219849D0 (en) 1992-09-19 1992-10-28 Hypoguard Uk Ltd Device
ES2154651T3 (es) 1992-10-15 2001-04-16 Gen Hospital Corp Bomba de infusion con biblioteca de medicamentos cargable electronicamente.
US5545147A (en) 1992-10-20 1996-08-13 Eli Lilly And Company Anti-backup improvement for hypodermic syringes
US5378233A (en) 1992-11-18 1995-01-03 Habley Medical Technology Corporation Selected dose pharmaceutical dispenser
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
GB9226423D0 (en) 1992-12-18 1993-02-10 Sams Bernard Incrementing mechanisms
DE69418314T2 (de) 1993-02-19 1999-12-16 Sanofi Sa Vorgefüllte spritze zur bewahrung und abgabe eines sterilen flüssigen arzneimittels
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
US5584815A (en) 1993-04-02 1996-12-17 Eli Lilly And Company Multi-cartridge medication injection device
ZA941881B (en) 1993-04-02 1995-09-18 Lilly Co Eli Manifold medication injection apparatus and method
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
SE9301494D0 (sv) 1993-04-30 1993-04-30 Kabi Pharmacia Ab A device for dosing liquid preparation
DK52393D0 (fr) 1993-05-05 1993-05-05 Novo Nordisk As
WO1995005848A1 (fr) 1993-08-24 1995-03-02 Novo Nordisk A/S Peptide-1 du type glucagon a action prolongee
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
CA2176462A1 (fr) 1993-11-19 1995-05-26 Larry P. Feigen Preparation transdermique de n-[n-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-l-.alpha.-aspartyl]-l-phenylalanine ou de ses esters et de leurs sels acceptables pharmaceutiquement
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5478316A (en) 1994-02-02 1995-12-26 Becton, Dickinson And Company Automatic self-injection device
US5514097A (en) 1994-02-14 1996-05-07 Genentech, Inc. Self administered injection pen apparatus and method
US5562623A (en) 1994-02-14 1996-10-08 Univec Single-use syringe assembly including spring clip lock and plunger
WO1995022560A1 (fr) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Formulations pharmaceutiques comprenant un facteur neurotrophique ciliaire
CA2189542A1 (fr) 1994-05-03 1995-11-09 Karen M. Oxenbýll Glucose-oxydase alcaline
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5750140A (en) 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU1595395A (en) 1994-06-15 1996-01-05 Interventional Research Technologies, Inc. Locking device for syringe or like instrument
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5725508A (en) 1994-06-22 1998-03-10 Becton Dickinson And Company Quick connect medication delivery pen
US5827232A (en) 1994-06-22 1998-10-27 Becton Dickinson And Company Quick connect medication delivery pen
US5440976A (en) 1994-08-23 1995-08-15 Fred Giuliano Adjustable dispensing stirrer for soluble sweeteners
EP0778034A4 (fr) 1994-08-24 1998-05-13 Eli Lilly Japan K K Appareil pour injections
US5549574A (en) 1994-08-30 1996-08-27 Eli Lilly And Company Cartridge assembly for use in a pen-type medicament injector
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
CA2157219C (fr) 1994-08-31 2010-10-05 Munehiro Noda Procede pour la purification d'albumine de serum humain recombinante
WO1996007324A1 (fr) 1994-09-09 1996-03-14 Novo Nordisk A/S Nettoyage, desinfection et conservation des lentilles de contact
US5549575A (en) 1994-09-13 1996-08-27 Becton Dickinson And Company Cartridge retainer assembly for medication delivery pen
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
DE69501406T2 (de) 1994-09-20 1998-05-20 Novonordisk As Verfahren zur behandlung einer wässrigen proteinlösung, um darin enthaltene mikroorganismen zu töten, ohne koagulation zu verursachen
ZA958073B (en) 1994-09-28 1996-04-23 Anthony William Manicom Method of and apparatus for administering a drug to a patient
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (ja) 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１組成物
AU4483496A (en) 1995-02-03 1996-08-21 Novo Nordisk A/S A method of designing alpha-amylase mutants with predetermined properties
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2213682C (fr) 1995-03-07 2009-10-06 Eli Lilly And Company Distributeur recyclable de medicament
CN1196061A (zh) 1995-03-17 1998-10-14 诺沃挪第克公司 胰岛素衍生物
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
CN1114613C (zh) 1995-06-02 2003-07-16 诺沃奇梅兹有限公司 蛋白质溶液的铝/铁处理和膜浓缩方法
CA2222411C (fr) 1995-06-02 2007-09-11 Novo Nordisk A/S Retrait automatique de tige de piston
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
KR100426438B1 (ko) 1995-06-13 2004-06-30 노보자임스 에이/에스 효소안정화제로서의4-치환-페닐-보론산
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
US5899879A (en) 1995-12-19 1999-05-04 Genesis Medical Technologies, Inc. Spring-actuated needleless injector
DE69722255T2 (de) 1996-02-23 2004-03-18 Novo Nordisk A/S Spritze mit elektronischer parameterdarstellung
US6440460B1 (en) 1996-03-05 2002-08-27 Allergan Sales, Inc. Pharmaceutical compositions containing buffered ortho ester polymers
IL126028A (en) 1996-03-12 2003-09-17 Novo Nordisk As Injection device with electronic presentation of set doses
WO1997036626A1 (fr) 1996-04-02 1997-10-09 Disetronic Licensing Ag Dispositif d'injection
CA2252620A1 (fr) 1996-04-24 1997-10-30 Novo Nordisk A/S Aiguille pour injection
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
BR9710130A (pt) 1996-07-03 1999-08-10 Alza Corp Formulações de peptídeos próticas não-aquosas
HUP9904152A3 (en) 1996-07-05 2000-05-29 Novo Nordisk As Flexible piston rod
UA41504C2 (uk) 1996-07-05 2001-09-17 Ново Нордіск А/С Пристрій для доставки відміряних доз лікарського засобу
WO1998001170A1 (fr) 1996-07-05 1998-01-15 Novo Nordisk A/S Mecanisme d'insertion automatique d'aiguille
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5962407A (en) 1996-07-26 1999-10-05 Kelly; Michael T. Loloatin derivatives and analogs
DK2016950T3 (da) 1996-08-08 2011-04-04 Amylin Pharmaceuticals Inc Farmaceutisk sammensætning omfattende et exendin-4-peptid
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
US5843036A (en) 1996-08-23 1998-12-01 Becton Dickinson And Company Non-dosing cartridge for an injection device
US5709662A (en) 1996-08-23 1998-01-20 Becton Dickinson France, S.A. Cartridge for an injection device
EP1826216A1 (fr) 1996-08-30 2007-08-29 Novo Nordisk A/S Dérivés de Glp-1
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5947934A (en) 1996-09-13 1999-09-07 Novo Nordisk A/S Dose display for an injection syringe
US6379339B1 (en) 1996-09-13 2002-04-30 Nova Nordisk A/S Syringe
DK0927057T3 (da) 1996-09-13 2003-09-01 Novo Nordisk As Dosisvisningsorgan til en injektionssprøjte
US6110149A (en) 1996-09-13 2000-08-29 Novo Nordisk A/S Syringe
DE69708894T2 (de) 1996-09-20 2002-08-22 Novo Nordisk A/S, Bagsvaerd Arbeitszylinder
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW524667B (en) 1996-12-05 2003-03-21 Pfizer Parasiticidal pyrazoles
US5954689A (en) 1996-12-20 1999-09-21 Novo Nordisk A/S Jet injector
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US6274553B1 (en) 1997-01-20 2001-08-14 Japan Energy Corporation Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
GB2321419B (en) 1997-01-27 2001-02-07 Medic Aid Ltd Atomizer
AU5652098A (en) 1997-02-04 1998-08-25 Novo Nordisk A/S A device for the administration of a liquid medicament suspension
DE29703820U1 (de) 1997-03-03 1998-07-02 Medico Development Investment Co., Ascona Injektionsgerät
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US20010020155A1 (en) 1997-03-25 2001-09-06 Soren Mikkelsen Injection system
AU6586298A (en) 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2236519C (fr) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methodes pour ameliorer le fonctionnement du gros intestin
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
RU2111019C1 (ru) 1997-05-22 1998-05-20 Сергей Александрович Хворостов Универсальный инъектор
KR100488038B1 (ko) 1997-05-23 2005-05-09 프레드라그 시키릭 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6003736A (en) 1997-06-09 1999-12-21 Novo Nordisk A/S Device for controlled dispensing of a dose of a liquid contained in a cartridge
AU7833698A (en) 1997-06-09 1998-12-30 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US6074372A (en) 1997-06-09 2000-06-13 Novo Nordisk A/S Dose setting mechanism and an injection syringe having such a dose setting mechanism
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US5961496A (en) 1997-06-17 1999-10-05 Novo Nordisk A/S Syringe with tiltable nut for quick piston disengagement
US6796970B1 (en) 1997-06-17 2004-09-28 Novo Nordisk A/S Dose setting device
JP3503129B2 (ja) 1997-06-30 2004-03-02 荒川化学工業株式会社 カラーフィルタ層用剥離剤およびカラーフィルタ用ガラス基板の再生方法
JP2001509426A (ja) 1997-07-11 2001-07-24 ノボ ノルディスク アクティーゼルスカブ 医療用具の設定の表示のための装置
JP2003514587A (ja) 1997-07-14 2003-04-22 ノボ ノルディスク アクティーゼルスカブ 射出部品
AU8333298A (en) 1997-07-14 1999-02-10 Novo Nordisk A/S Cylinder ampoule
DE19730999C1 (de) 1997-07-18 1998-12-10 Disetronic Licensing Ag Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US5957896A (en) 1997-08-11 1999-09-28 Becton, Dickinson And Company Medication delivery pen
FR2767479B1 (fr) 1997-08-22 1999-10-22 Aguettant Lab Dispositif d'injection de medicament
AU9202398A (en) 1997-09-29 1999-04-23 Becton Dickinson & Company Injection device and drug cartridge for preventing cross-use of the device and drug cartridge
CA2306024C (fr) 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Pulverisation ou capsule buccale, polaire et non polaire
DK1025126T3 (da) 1997-10-24 2003-08-04 Genentech Inc Oprensning af molekyler
IL135400A0 (en) 1997-10-24 2001-05-20 Novo Nordisk As Aggregates of human insulin derivatives
US6312413B1 (en) 1997-10-30 2001-11-06 Novo Nordisk A/S Cylinder ampoule
EP1049486A4 (fr) 1997-12-05 2006-01-04 Lilly Co Eli Formulations de glp-1
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DE29721752U1 (de) 1997-12-09 1998-02-12 Siemens AG, 80333 München Crimpkontakt für Stecksysteme
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JPH11249087A (ja) 1997-12-18 1999-09-17 Tome:Kk コンタクトレンズ用液剤
WO1999034764A2 (fr) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Compositions pharmaceutiques a agoniste d'amyline, contenant de l'insuline
WO1999034822A1 (fr) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Formulations de peptides agonistes d'amyline
BR9906857A (pt) 1998-01-30 2000-11-14 Novo Nordisk As Seringas de injeção
EP0978565B1 (fr) 1998-01-30 2007-10-10 Asubio Pharma Co., Ltd. Procede de production de peptide au moyen d'un peptide accessoire
AU766653B2 (en) 1998-02-13 2003-10-23 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
JP4677095B2 (ja) 1998-02-13 2011-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
CA2320993C (fr) 1998-02-13 2008-05-06 Graham Francois Duirs Dispositif servant a administrer un medicament
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6096010A (en) 1998-02-20 2000-08-01 Becton, Dickinson And Company Repeat-dose medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1056774A1 (fr) 1998-02-27 2000-12-06 Novo Nordisk A/S Derives de glp-1 tronques a l'extremite n-terminale
EP1060191B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives d'analogues de glp-1
WO1999043341A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de glp-1 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
WO1999043707A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
AU2612599A (en) 1998-03-13 1999-10-11 Novo Nordisk A/S Stabilized aqueous peptide solutions
AU3772199A (en) 1998-05-01 1999-11-23 University Of Tennessee Research Corporation, The Flow cytometric characterization of amyloid fibrils
US6281225B1 (en) 1998-06-11 2001-08-28 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
WO2000002605A1 (fr) 1998-07-08 2000-01-20 Novo Nordisk A/S Dispositif medical d'administration et ensemble cartouche destine a etre utilise avec celui-ci
JP2002524514A (ja) 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
US6033376A (en) 1998-09-30 2000-03-07 Allergan Sales, Inc. Wound shaper sleeve
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6605067B1 (en) 1998-11-20 2003-08-12 Novo Nordisk A/S Injection needle
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
CA2358107C (fr) 1998-12-22 2011-08-23 Eli Lilly And Company Formulation de longue conservation de peptide-1 de type glucagon
DE29900482U1 (de) 1999-01-14 2000-08-31 Medico Development Investment Co., Ascona Injektionsgerät
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
ATE390960T1 (de) 1999-02-14 2008-04-15 Pfeiffer Erich Gmbh & Co Kg Spender für fliessfähige medien
US6258062B1 (en) 1999-02-25 2001-07-10 Joseph M. Thielen Enclosed container power supply for a needleless injector
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
ATE409193T1 (de) 1999-03-17 2008-10-15 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
SE9901366D0 (sv) 1999-04-16 1999-04-16 Pharmacia & Upjohn Ab Injector device and method for its operation
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
KR20020059255A (ko) 1999-06-17 2002-07-12 린다 에스. 스티븐슨 저온 저장을 개선하기 위한 ＰＥＧ-Ｈｂ를 사용하는 연속심장 관류 보존
DE60036367T2 (de) 1999-06-21 2008-05-29 Eli Lilly And Co., Indianapolis Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
EP1196189A2 (fr) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Therapie anti diabete a agents multiples
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
ATE318157T1 (de) 1999-08-05 2006-03-15 Becton Dickinson Co Stiftförmige medikamentenabgabevorrichtung
TW453884B (en) 1999-09-16 2001-09-11 Novo Nordisk As Dose setting limiter
ATE309820T1 (de) 1999-09-20 2005-12-15 Lilly Co Eli Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
US6514230B1 (en) 1999-10-12 2003-02-04 Novo Nordisk A/S Air shot mechanism for electronic injection devices
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
ATE288765T1 (de) 1999-12-16 2005-02-15 Lilly Co Eli Polypeptidzusammensetzungen mit verbesserter stabilität
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1250126A2 (fr) 2000-01-11 2002-10-23 Novo Nordisk A/S Distribution transepitheliale de derives de glp-1
WO2001052937A1 (fr) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Systeme tampon melange pour la stabilisation de preparations pour polypeptides
AU2001232735A1 (en) 2000-01-27 2001-08-07 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
EP1396499A3 (fr) 2000-01-27 2004-12-29 Eli Lilly And Company Procédé de solubilisation de composés 1-peptidiques de type glucagon (GLP-1)
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
US6692472B2 (en) 2000-05-04 2004-02-17 Novo Nordisk A/S Injection device, a preassembled dose setting and injection mechanism for an injection device, and a method of assembling an injection device
WO2001087322A2 (fr) 2000-05-17 2001-11-22 Bionebraska, Inc. Preparations pharmaceutiques peptidiques
US6716198B2 (en) 2000-05-18 2004-04-06 Novo Nordisk A/S Injection device
US6547763B2 (en) 2000-05-18 2003-04-15 Novo Nordisk A/S Dose display for injection device
US6547764B2 (en) 2000-05-31 2003-04-15 Novo Nordisk A/S Double pointed injection needle
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
AU6479101A (en) 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
US6369419B1 (en) 2000-06-23 2002-04-09 International Business Machines Corporation Self-aligned near surface strap for high density trench DRAMS
EP1409042B1 (fr) 2000-07-14 2008-02-20 Novo Nordisk A/S Dispositif d'administration de medicament liquide et methode pour la reduction des gouttes
WO2002024257A1 (fr) 2000-09-22 2002-03-28 Novo Nordisk A/S Dispositif pour l'apport d'un medicament
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
PT1724284E (pt) 2000-12-07 2009-09-30 Lilly Co Eli Proteínas de fusão com glp-1
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4278382B2 (ja) 2001-02-14 2009-06-10 ノボ ノルディスク アクティーゼルスカブ 電子制御される注射器即ち注入装置
DE60226702D1 (de) 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
JP2004518756A (ja) 2001-03-07 2004-06-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
ATE355093T1 (de) 2001-05-16 2006-03-15 Lilly Co Eli Arzneimitteleinspritzvorrichtung mit rückstellung erleichternder antriebsanordnung
WO2002098445A1 (fr) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preparation de proteines
GB0113881D0 (en) 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
WO2003020201A2 (fr) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-melanges de polypeptide glp-1 et d'insuline basale
US6676641B2 (en) 2001-09-05 2004-01-13 Futura Medical Technologies, Inc. Retractable hypodermic syringe
BR0213377A (pt) 2001-10-18 2006-05-23 Bristol Myers Squibb Co mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
WO2003074029A1 (fr) 2002-03-07 2003-09-12 Vectura Limited Formulations a base de particules multiples a fusion rapide pour administration orale
WO2003077937A1 (fr) 2002-03-15 2003-09-25 Natimmune A/S Compositions pharmaceutiques contenant une lectine liant le mannose (mbl)
EP1494704A1 (fr) 2002-04-04 2005-01-12 Novo Nordisk A/S Agoniste glp-1 et complications cardio-vasculaires
MXPA05000414A (es) 2002-07-09 2005-07-22 Sandoz Ag Formulaciones liquidas con alta concentracion de hormona de crecimiento humano (hgh) comprendiendo fenol.
US6945961B2 (en) 2002-07-10 2005-09-20 Novo Nordisk A/S Injection device
WO2004007003A1 (fr) 2002-07-10 2004-01-22 Novo Nordisk A/S Dispositif d'injection a limiteur de dosage
EP1391794A1 (fr) 2002-07-23 2004-02-25 Novo Nordisk A/S Dispositif muni d'indicateur de temps
EP1539279B1 (fr) 2002-08-29 2006-06-28 Novo Nordisk A/S Dispositif d'injection se chargeant par l'avant
AU2003265179B2 (en) 2002-09-24 2008-07-31 Shl Medical Ab Injecting device
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
DE60321473D1 (de) 2002-09-25 2008-07-17 Novo Nordisk As Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
WO2004037168A2 (fr) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Traitement de la pancreatite avec de l'amyline
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
EP1610811A4 (fr) 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc Prevention et traitement d'arythmies cardiaques
US20050019400A1 (en) 2003-01-27 2005-01-27 Deveney Thomas William Controlled-release drug delivery system
GB0304824D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0306642D0 (en) 2003-03-22 2003-04-30 Dca Design Int Ltd Improvements in and relating to an injector for a medical product
GB0308267D0 (en) 2003-04-10 2003-05-14 Dca Design Int Ltd Improvements in and relating to a pen-type injector
WO2004089985A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
MXPA05013048A (es) 2003-06-03 2006-03-02 Novo Nordisk As Composiciones peptodicas farmaceuticas estabilizadas.
CN1812807A (zh) * 2003-06-03 2006-08-02 诺沃挪第克公司 稳定化的药物肽组合物
DK1656170T3 (en) 2003-08-12 2019-04-29 Lilly Co Eli Drug delivery device with three screw threads for mechanical advantage
EP1663289A2 (fr) 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Procedes pour traiter ou ameliorer des maladies et des troubles associes a la ghreline
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
DE602004023961D1 (de) 2003-11-04 2009-12-17 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
EP3858387A1 (fr) 2003-11-06 2021-08-04 Seagen Inc. Composés de monométhylvaline capables de conjugaison aux ligands
EP1684793B1 (fr) 2003-11-13 2011-09-21 Novo Nordisk A/S Composition pharmaceutique comprenant un analogue insulinotrope de glp-1(7-37), de l'insuline-asp(b28), et un surfactant
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
WO2005058252A2 (fr) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions pharmaceutiques glp-1
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
WO2006083254A1 (fr) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Peptides de la famille amyline et procedes de production et d'utilisation desdits peptides
EP1765406A4 (fr) 2004-05-21 2012-11-28 Mediplex Corp Delivrance d'agents permettant d'ameliorer l'absorption mucosale d'agents therapeutiques
US7448385B2 (en) 2004-06-07 2008-11-11 Purepharm Inc. Nasal adaptation of an oral inhaler device
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
WO2006000567A2 (fr) 2004-06-28 2006-01-05 Novo Nordisk A/S Methodes de traitement du diabete
EP1789075A4 (fr) 2004-08-25 2009-07-01 Uab Research Foundation Substances ameliorant l'absorption destinees a l'administration de medicaments
JP4926069B2 (ja) 2004-11-01 2012-05-09 アミリン・ファーマシューティカルズ，インコーポレイテッド 肥満ならびに肥満関連疾患および障害の治療方法
CN101056650A (zh) 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
WO2006051103A2 (fr) 2004-11-12 2006-05-18 Novo Nordisk A/S Préparations stables de peptides
CA2587710C (fr) 2004-11-16 2014-10-21 Elan Pharma International Ltd. Formulations injectables de nanoparticules d'olanzapine
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
ES2633917T3 (es) 2005-01-21 2017-09-26 Novo Nordisk A/S Dispositivo de inyección automático con un mecanismo de liberación superior
EP2620450B1 (fr) 2005-03-08 2018-11-07 Pfizer Products Inc. Compositions d'anticorps anti-CTLA-4
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1912666A2 (fr) 2005-07-22 2008-04-23 Amylin Pharmaceuticals, Inc. Utilisation d'amyline et d'agonistes d'amyline comme agents cardioprotecteurs ou myoprotecteurs
WO2007022518A2 (fr) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. Nouvelles utilisations de proteines glucoregulatoires
KR20080081175A (ko) 2005-12-19 2008-09-08 코멘티스, 인코포레이티드 안구 투여를 위한 국소 메카밀라민 제형 및 그것의 사용
EP3766518A1 (fr) 2005-12-29 2021-01-20 Boehringer Ingelheim Animal Health USA Inc. Composition immunogène pcv2 pour diminuer les symptômes cliniques chez les porcs
BRPI0710651A2 (pt) 2006-04-13 2011-08-23 Sod Conseils Rech Applic composições farmacêuticas de hglp-1, expedina-4 e seus análogos e uso das mesmas
CA2658286A1 (fr) 2006-07-18 2008-01-24 Centocor, Inc. Mimetiques de la glp-1 humaine, compositions, procedes et utilisations
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
IL290847B1 (en) 2007-04-23 2024-07-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and their uses
EP2190460B1 (fr) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides dérivés avec a-b-c-d et utilisation thérapeutique de ceux-ci
US20100311643A1 (en) 2007-09-11 2010-12-09 Dorian Bevec Use of glp-1 as a therapeutic agent
WO2009051992A1 (fr) 2007-10-19 2009-04-23 Bausch & Lomb Incorporated Compositions et procédés de traitement de maladies mettant en jeu une angiogenèse oculaire par inhibition d'une ou plusieurs tyrosine kinases de récepteurs sélectionnés
KR20100098628A (ko) 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
EP2231191A2 (fr) 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation de conjugués de peptides insulinotropes
ES2662501T3 (es) 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
CN102458521B (zh) 2009-06-04 2014-06-04 诺沃—诺迪斯克保健股份有限公司 具有活塞联接布置的混合设备
WO2011012719A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Composition d'insuline à action prolongée
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
WO2011050008A2 (fr) 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Polythérapie comprenant l'administration d'un amylinomimétique et d'un peptidomimétique de pyy pour obtenir une perte de poids et pour traiter l'obésité et les états pathologiques et les troubles métaboliques associés
SG181487A1 (en) 2009-12-10 2012-07-30 Merck Patent Gmbh Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US8648041B2 (en) 2009-12-16 2014-02-11 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2011104378A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides de traitement de l'obésité
WO2011109787A1 (fr) 2010-03-05 2011-09-09 Conjuchem, Llc Méthodes d'administration de peptides insulinotropes
WO2011109784A1 (fr) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation de conjugués peptidiques insulinotropiques
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
CN103200956A (zh) 2010-07-28 2013-07-10 安米林药品有限责任公司 具有稳定区域的glp-1受体激动剂化合物
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
ES2913803T3 (es) 2010-11-09 2022-06-06 Novo Nordisk As Derivados de GLP-1 diacilados
CN103298457A (zh) 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 Glp-1组合物
CN103391768B (zh) 2011-02-04 2016-08-10 第一医疗保健有限公司 治疗慢性炎症和炎性疾病的组合物和方法
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
JP6247205B2 (ja) 2011-06-10 2017-12-13 ノヴォ ノルディスク アー／エス ポリペプチド
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US9132170B2 (en) 2011-07-29 2015-09-15 Case Western Reserve University Compositions and methods for treating cognitive deficits
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013083826A2 (fr) 2011-12-09 2013-06-13 Novo Nordisk A/S Agonistes du glp-1
WO2013127779A1 (fr) 2012-03-01 2013-09-06 Novo Nordisk A/S Promédicaments à base de glp-1
CN102579350B (zh) 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
CA2868438A1 (fr) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Polynucleotides modifies destines a la production de proteines nucleaires
US9814761B2 (en) 2012-04-03 2017-11-14 Trustees Of Boston University Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
JP6227629B2 (ja) 2012-04-19 2017-11-08 ノヴォ ノルディスク アー／エス ヒトアミリン類似体
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
WO2013167455A1 (fr) 2012-05-08 2013-11-14 Novo Nordisk A/S Dérivés du glp-1 à double acylation
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
LT2861608T (lt) 2012-06-19 2019-07-10 Debiopharm International Sa (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-nafthidrin-3-il)akrilamido provaisto dariniai
CA2877056A1 (fr) 2012-07-01 2014-01-09 Novo Nordisk A/S Utilisation de peptides glp-1 a action longue
CN104717972A (zh) * 2012-10-17 2015-06-17 诺和诺德A/S（股份有限公司） 用于口服肽递送的脂肪酸酰化氨基酸
CA3209602A1 (fr) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Compositions pharmaceutiques
EP2991671B1 (fr) 2013-05-02 2018-08-15 Novo Nordisk A/S Dosage par voie orale de composés glp-1
EA030958B1 (ru) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Ингибиторы акк и их применение
JP2016522241A (ja) 2013-06-21 2016-07-28 ノヴォ ノルディスク アー／エス インスリンで治療された及び／又は１型糖尿病に罹患している患者におけるｇｌｐ−１受容体作動薬の新規の使用
CN105377884B (zh) 2013-07-04 2021-07-20 诺和诺德股份有限公司 Glp-1样肽的衍生物和其用途
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015155151A1 (fr) 2014-04-07 2015-10-15 Novo Nordisk A/S Composés glp -1 à double acylation
US20180021409A1 (en) 2014-06-25 2018-01-25 Glaxosmithkline Llc Pharmaceutical Composition
WO2016001862A1 (fr) 2014-07-04 2016-01-07 Wockhardt Limited Formulations à libération prolongée d'insulines
WO2016038521A1 (fr) 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques de liraglutide
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
CN105777872B (zh) * 2014-12-16 2019-06-07 深圳翰宇药业股份有限公司 一种萨摩鲁肽的纯化方法
US20190060410A1 (en) 2015-05-13 2019-02-28 Xiaoni LIU Pharmaceutical Formulation Comprising GLP-1 Analogue and Preparation Method Thereof
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3423481B1 (fr) 2016-03-03 2020-10-07 Novo Nordisk A/S Dérivés glp-1 et leurs utilisations
BR112018072020A2 (pt) 2016-04-28 2019-02-12 Novo Nordisk A/S semaglutida em condições cardiovasculares
JP2019535835A (ja) 2016-11-22 2019-12-12 バイオコン リサーチ リミテッドＢｉｏｃｏｎ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Ｇｌｐ−１類似体の医薬組成物
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
KR20190124704A (ko) 2017-01-24 2019-11-05 마크레젠, 인크. 아포지질단백질 모방체를 이용하는, 나이 관련 황반 변성 및 기타 안질환의 치료
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
US11590206B2 (en) 2017-12-21 2023-02-28 Sanofi Liquid pharmaceutical composition
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations

Also Published As

Publication number Publication date
RS65380B1 (sr) 2024-04-30
US20210085755A1 (en) 2021-03-25
CO2020002647A2 (es) 2020-06-09
US20200164042A1 (en) 2020-05-28
MA46990A (fr) 2019-05-01
PH12020550051A1 (en) 2020-10-19
HUE066356T2 (hu) 2024-07-28
CN111050750A (zh) 2020-04-21
KR20200044016A (ko) 2020-04-28
US11752198B2 (en) 2023-09-12
AR112480A1 (es) 2019-10-30
MX2020001525A (es) 2020-03-20
RU2020109402A (ru) 2021-09-03
PE20211202A1 (es) 2021-07-05
ES2976496T3 (es) 2024-08-02
BR112020002804A2 (pt) 2020-07-28
EP3474820B1 (fr) 2024-02-07
TW202304501A (zh) 2023-02-01
TW202224670A (zh) 2022-07-01
AU2018321157B2 (en) 2024-03-28
CL2020000422A1 (es) 2020-07-10
IL272232A (en) 2020-03-31
PL3474820T3 (pl) 2024-05-13
HRP20240485T1 (hr) 2024-07-05
CL2021001430A1 (es) 2021-11-12
JP2019528237A (ja) 2019-10-10
EP3474820C0 (fr) 2024-02-07
WO2019038412A1 (fr) 2019-02-28
TWI762706B (zh) 2022-05-01
AU2018321157A1 (en) 2020-03-19
TWI783890B (zh) 2022-11-11
TWI847306B (zh) 2024-07-01
CA3082033A1 (fr) 2019-02-28
TW201912147A (zh) 2019-04-01
JP6633777B2 (ja) 2020-01-22
US20240016896A1 (en) 2024-01-18
KR102665710B1 (ko) 2024-05-14
IL272232B1 (en) 2023-03-01
CN111050750B (zh) 2024-09-24
EP4360651A3 (fr) 2024-07-17
AU2024204151A1 (en) 2024-07-11
RU2020109402A3 (fr) 2022-01-25
EP3474820A1 (fr) 2019-05-01
SG11202000940XA (en) 2020-02-27
US20240216475A1 (en) 2024-07-04
US10888605B2 (en) 2021-01-12
EP4360651A2 (fr) 2024-05-01

Similar Documents

Publication Publication Date Title
MA46990B1 (fr) Compositions glp-1 et ses utilisations
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
DOP2020000023A (es) Nuevos derivados de quinolina
MA41060A (fr) Compositions comprenant des souches bactériennes
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MX2023007137A (es) Nanomateriales que comprenden acetales unidos a ésteres.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
WO2015070224A3 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
CL2020002891A1 (es) Nuevos derivados de quinolina
MX2020008125A (es) Composiciones que comprenden berberina.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
UY37971A (es) Derivados de indol macrocíclicos sustituidos
MX2022009844A (es) Composiciones y usos del peptido similar al glucagon-1 (glp-1).
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2020012800A (es) Cannabinoides y usos de los mismos.
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
EP4275761A3 (fr) Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations